Metastatic brain tumors develop when cancer cells from elsewhere in the body, most often the lung, breast, kidney, colon, or melanoma, travel through the bloodstream and settle in the brain. They're the most common type of brain tumor in adults, outnumbering primary brain tumors overall. A patient may have a single (solitary) lesion or several (multiple) lesions at once.
The treatment decision isn't based on the brain findings alone. It's shaped together with the status of the primary cancer, the number, size, and location of the brain lesions, and the patient's overall condition, which is why this is usually a joint decision made with the oncology team.
Symptoms vary with the number, size, and location of the lesions. Common presentations include:
Contrast-enhanced MRI is the standard diagnostic tool. In patients with a known history of cancer, it typically shows one or more well-defined lesions with pronounced surrounding edema. If the primary cancer hasn't been identified yet, a body-wide scan (CT or PET-CT) is used to find its source. When the diagnosis remains uncertain, a biopsy is used to confirm it.
Treatment is tailored to the number, size, and location of the brain lesions, along with the patient's overall condition, while treatment of the primary cancer (chemotherapy, targeted therapy, immunotherapy) continues in parallel.
Surgical removal comes into play when a lesion is large, is causing a significant neurological deficit, is the only lesion present, or sits in the posterior fossa and is causing obstructive hydrocephalus. Surgery is usually followed by stereotactic radiosurgery directed at the resection cavity.
Stereotactic radiosurgery (SRS) is a surgery-free option for small, limited-number (oligometastatic) lesions.
Whole-brain radiotherapy (WBRT) is generally reserved for patients with numerous lesions or a general condition that isn't well suited to surgery or radiosurgery.
Explore how the decision is made for metastatic brain tumors, and what a typical treatment course looks like.
Contrast-enhanced MRI establishes the number, size, and location of the lesions; if the primary cancer isn't yet known, a body-wide scan helps locate it.
The status of the primary cancer, available systemic treatment options, and the patient's overall performance status are reviewed together with the oncology team.
From here, the right path depends on the number, size, and location of the lesions, and the patient's overall condition. Tap a profile to see more.
Regular MRI monitoring continues in coordination with the ongoing systemic treatment of the primary cancer.
Imaging, coordination with the oncology team, labs, anesthesia clearance, and neuronavigation planning.
Resection is carried out; neuronavigation and intraoperative ultrasound are very helpful in cases that call for them. Larger tumors or higher-risk locations warrant a night of ICU observation.
Neurological checks, wound care, and close monitoring continue; the patient is gradually mobilized.
Patients with a stable neurological exam go home with instructions.
Pathology results are finalized during this window. Once the surgical wound has healed, stereotactic radiosurgery directed at the resection cavity is planned and delivered to reduce the risk of recurrence.
Regular MRI monitoring continues alongside systemic treatment of the primary cancer, chemotherapy, targeted therapy, or immunotherapy, coordinated with the oncology team.
Shown for a typical, uncomplicated case. Individual treatment course may vary.